Amendments to the Specification:

Please replace the paragraph at page 1, lines 4-20, with the following rewritten paragraph:

This application is a continuation-in-part of U.S. Patent Application No. 09/593,793, filed June 13, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/570,737, filed May 12, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/568,100, filed May 9, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/536,857, filed March 27, 2000, now abandoned, which is a continuation-in-part of U. S. Patent Application No. 09/483,672, filed January 14, 2000, now abandoned, which is a continuation-in-part of U.S. Patent Application No. 09/439,313, filed November 12, 1999, now Patent No. 6,329,505, which is a continuation-in-part of U.S. Patent Application No. 09/352,616, filed July 13, 1999, now Patent No. 6,395,278,, which is a continuation-in-part of U.S. Patent Application No. 09/288,946, filed April 9, 1999, now abandoned, which is a continuation-in-part of U.S. Patent Application No. 09/232,149, filed January 15, 1999, now Patent No. 6,465,611, which is a continuation-in-part of U.S. Patent Application No. 09/159,812, filed September 23, 1998, now Patent No. 6,613,872, which is a continuation-in-part of U.S. Patent Application No. 09/115,453, filed July 14, 1998, now Patent No. 6,657,056, which is a continuation-in-part of U.S. Patent Application No. 09/030,607, filed February 25, 1998, now Patent No. 6,262,245, which is a continuation-in-part of U.S. Patent Application No. 09/020,956, filed February 9, 1998, now Patent No. 6,261,562, which is a continuation-in-part of U.S. Patent Application No. 08/904,804, filed August 1, 1997, now abandoned, which is a continuation-in-part of U.S. Patent Application No. 08/806,099, filed February 25, 1997, now abandoned.

Please replace the paragraph beginning at page 8, line 14, with the following rewritten paragraph:

Figure 8 illustrates the results of epitope mapping studies on P501S. The peptides used in the study are shown from left to right at the bottom of the figure, as follows: MDRLVQRFGTRAVYLASVA (SEQ ID NO: 489), YLASVAAFPVAAGATCLSHS (SEQ ID

NO: 490), TCLSHSVAVVTASAALTGFT (SEQ ID NO: 491), ALTGFTFSALQILPYTLASL (SEQ ID NO: 492), YTLASLYHREKQVFLPKYRG (SEQ ID NO: 493), LPKYRGDTGGASSEDSLMIS (SEQ ID NO: 494), DSLMTSFLPGPKPGAPFPNG (SEQ ID NO: 495), APFPNGHVGAGGSGLLPPPPA (SEQ ID NO: 496), LLPPPPALCGASACDVSVRV (SEQ ID NO: 497), DVSVRVVVGEPTEARVVPGR (SEQ ID NO: 498), RVVPGRGICLDLAILDSAFL (SEQ ID NO: 499), LDSAFLLSQVAPSLFMGSIV (SEQ ID NO: 500), FMGSIVQLSQSVTAYMVSAA (SEQ ID NO: 501).

Please replace the paragraph beginning at page 8, line 15, with the following rewritten paragraph:

Figure 9 is a schematic representation of the P501S protein (SEQ ID NO: 113) showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Please replace the paragraph beginning at page 8, line 20, with the following rewritten paragraph:

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S. The depicted sequence corresponding to peptide P501S 306-320 is set forth in SEQ ID NO: 519 and the sequence corresponding to P501S 296-320 is set forth in SEQ ID NO: 520.

Please replace the paragraph beginning at page 8, line 22, with the following rewritten paragraph:

Figures 12A(1), 12A(2), 12A(3), and B are the full-length cDNA (SEQ ID NO:~~591~~777) and predicted amino acid (SEQ ID NO:~~592~~778) sequences, respectively, for the clone P788P.